Diabetes and chronic liver disease: Etiology and pitfalls in monitoring

Clinical Diabetes

Volumn 28, Issue 4, 2010, Pages 139-144

  Blendea, Mihaela C ^a   Thompson, Michael J ^b   Malkani, Samir ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; RIBAVIRIN;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; HEMOLYSIS; HEPATITIS C; HUMAN; NONALCOHOLIC FATTY LIVER; PATIENT MONITORING; TREATMENT OUTCOME;

EID: 78149440943     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.28.4.139     Document Type: Article

References (58)

1. Institute of Medcine: Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C [consensus report]. Available online from www.iom.edu/Reports/2010/Hepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C.aspx. Accessed 3 May 2010
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395, 2004
3. Angulo P: GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25:883-889, 2007
4. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P: Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105:1567-1573, 2010
5. Hasin DS, Stinson FS, Ogburn E, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 64:830-842, 2007
6. National Institute of Alcohol Abuse and Alcoholism: Age-specific and age-adjusted death rates for cirrhosis with and without mention of alcohol, United States, 1970-2005. Available online from http://www.niaaa.nih.gov/Resources/DatabaseResources/QuickFacts/Liver/cirmrt3b.htm. Accessed 12 May 2010
7. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP: Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 318:1355-1362, 1988
8. Crooks CJ, West J, Solaymani-Dodaran M, Card TR: The epidemiology of haemochromatosis: a population-based study. Aliment Pharmacol Ther 29:183-192, 2009
9. Petrides AS: Liver disease and diabetes mellitus. Diabetes Rev 2:1-18, 1994
10. García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H: Hepatogenous diabetes: current views of an ancient problem. Ann Hepatol 8:13-20, 2009
11. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P: Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 5:26-34, 2009
12. Kuriyama S, Miwa Y, Fukushima H, Nakamura H, Toda K, Shiraki M, Nagaki M, Yamamoto M, Tomita E, Moriwaki H: Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease. J Clin Biochem Nutr 40:116-122, 2007
13. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R: Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 82:2606-2612, 2008
14. Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H, Inamori M, Nozaki Y, Akiyama T, Takahashi H, Abe Y, Kubota K, Iwasaki T, Terauchi Y, Togo S, Nakajima A: Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 14:600-607, 2007
15. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641, 2005
16. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C: Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29:2462-2466, 2006
17. Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G: Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 103:2481-2487, 2008
18. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN: Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 54:2699-2705, 2009
19. Kumar M, Choudhury A, Manglik N, Hissar S, Rastogi A, Sakhuja P, Sarin SK: Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol 104:76-82, 2009
20. Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS: Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 23:779-782, 2008
21. El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-468, 2004
22. American Diabetes Association: Standards of medical care in diabetes-2010. Diabetes Care 33 (Suppl. 1):S11-S61, 2010
23. Hodge JE: The Amadori rearrangement. Adu Carbohydr Chem 10:169-205, 1955
24. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 25:275-278, 2002
25. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1C-Derived Average Glucose Study Group: Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473-1478, 2008
26. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
27. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
28. Schnedl WJ, Lahousen T, Krause R, Wallner SJ, Piswanger-Soelkner C, Lipp RW: Evaluation of conditions associated with glycated hemoglobin values below the reference range. Clin Lab 53:179-181, 2008
29. Molinaro RJ: Targeting HbA1c: standardization and clinical laboratory measurement. MLO Med Lab Obs 40:10-14, 16-19, 2008
30. Johnson RN, Metcalf PA, Baker JR: Fructosamine: a new approach to the estimation of serum glycosylprotein: an index of diabetic control. Clin Chim Acta 127:87-95, 1983
31. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM; American Diabetes Association: Tests of glycemia in diabetes. Diabetes Care 27 (Suppl. 1):S91-S93, 2004
32. Schleicher ED, Olgemöller B, Wiedenmann E, Gerbitz KD: Specific glycation of albumin depends on its half-life. Clin Chem 39:625-628, 1993
33. Hill RP, Hmdle EJ, Howey JEA, Lemon M, Lloyd DR: Recommendations for adopting standard conditions and analytical procedures in the measurement of serum fructosamine concentration. Ann Clin Biochem 27:413-424, 1990
34. MacDonald D, Pang CP, Cockram CS, Swaminathan R: Fructosamine measurements in serum and plasma. Clin Chim Acta 168:247-252, 1987
35. Chen HS, Wu TE, Lin HD, Jap TS, Hsiao LC, Lee SH, Lin SH: Hemoglobin A1C and fructosamine for assessing glycemic control in diabetic patients with CKD Stages 3 and 4. Am J Kidney Dis 55:867-874, 2010
36. Jerntorp P, Sundkvist G, Fex G, Jeppsson JO: Clinical utility of serum, fructosamine in diabetes mellitus compared with hemoglobin A1C. Clin Chim Acta 175:135-142, 1987
37. Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, Lapolla A, Mosca A: Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 40:1398-1405, 2007
38. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y; Osaka CKD Expert Research Group: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 18:896-903, 2007
39. Morse EE: Mechanisms of hemolysis in liver disease. Ann Clin Lab Sci 20:169-174, 1990
40. Lahousen T, Hegenbarth K, Ille R, Lipp RW, Krause R, Little RR, Schnedl WJ: Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 10:2284-2286, 2004
41. Gurudu SR, Mittal SK, Shaber M, Gamboa E, Michael S, Sigal LH: Autoimmune hepatitis associated with autoimmune hemolytic anemia and anticardiolipin antibody syndrome. Dig Dis Sci 45:1878-1880, 2000
42. Kondo H, Kajii E, Oyamada T, Kasahara Y: Direct antiglobulin test negative autoimmune hemolytic anemia associated with autoimmune hepatitis. Int J Hematol 68:439-443, 1998
43. Coban E, Ozdogan M, Timuragaoglu A: Effect of iron deficiency anemia on the levels of hemoglobin A1C in nondiabetic patients. Acta Haematol 112:126-128, 2004
44. Tarim O, Küçükerdogan A, Günay U, Eralp O, Ercan I: Effects of iron deficiency anemia on hemoglobin A1C in type 1 diabetes mellitus. Pediatr Int 41:357-362, 1999
45. Kim C, McKeever BK, Herman WH, Beckles G: Association between iron deficiency and A1C levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 33:780-785, 2010
46. Hashimoto K, Noguchi S, Morimoto Y, Hamada S, Wasada K, Imai S, Murata Y, Kasayama S, Koga M: A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care 31:1945-1948, 2008
47. Hashimoto K, Osugi T, Noguchi S, Morimoto Y, Wasada K, Imai S, Waguri M, Toyoda R, Fujita T, Kasayama S, Koga M: A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care 33:509-511, 2010
48. Aslan D, Gursel T: The usefulness of glycosylated hemoglobin (HbA1c) in discriminating between iron deficiency and thalassemia. Pediatr Hematol Oncol 23:307-315, 2006
49. Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L: Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency. J Intern Med 227:133-136, 1990
50. Takeuchi J, Takada A: Hypoproteinemia in liver diseases. Japan J Med 7:305-307, 1968
51. Weigand K: The regulation of serum albumin in physiological and pathological conditions. Klin Wochenschr 55:295-305, 1977
52. Takada K, Kobayashi J, Takeuchi J: Gastroenteric clearance of albumin in liver cirrhosis: relative protein-losing gastroenteropathy. Digestion 3:154-164, 1970
53. Koga M, Kasayama S, Kanehara H, Bando Y: CLD (chronic liver diseases): HbA1c as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract 81:258-262, 2008
54. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G: Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 13:3351-3357, 2006
55. Krishnan SM, Dixit NM: Estimation of red blood cell lifespan from alveolar carbon monoxide measurements. Transl Res 154:15-17, 2009
56. Robertson M: Artificially low HbA1c associated with treatment with ribavirin. BMJ 336:505, 2008
57. Tolman KG, Fonseca V, Dalpiaz A, Tan MH: Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30:734-743, 2007
58. McNeely M: Case study: diabetes in a patient with cirrhosis. Clinical Diabetes 22:42-43, 2004